<DOC>
	<DOC>NCT01997125</DOC>
	<brief_summary>The purpose of this clinical study is to allow the investigation of the Neural Bridging System for participants with tetraplegia to assess if the investigational device can reanimate a paralyzed limb under voluntary control by the participant's thoughts.</brief_summary>
	<brief_title>Reanimation in Tetraplegia</brief_title>
	<detailed_description>This study plans to enroll participants who have been diagnosed with C4- C6 ASIA A spinal cord injuries (motor and sensory complete neurologic injuries), who are more than 1 year post injury, and who are neurologically stable.</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Quadriplegia</mesh_term>
	<criteria>Must be 21 years or older. Must be tetraplegic (C4 C6 ASIA A). 12 months post injury and neurologically stable. Participant is willing to comply with all followup evaluations at the specified times. Participant is able to provide informed consent prior to enrollment in the study. The participant is fluent in English. Participant must have a caregiver willing to participate in the study who will provide care for the surgical site. No active wound healing or skin breakdown issues. No history of poorly controlled autonomic dysreflexia. Medical contraindications for general anesthesia, craniotomy, or surgery. Diagnosis of acute myocardial infarction or cardiac arrest within previous 6 months. Participants with any type of destruction and/or damage to the motor cortex region as determined by MRI. History of psychiatric disturbance or dementia Other implantable devices such as heart/brain pacemakers Participants who rely on ventilators Comorbid conditions that would interfere with study activities or response to treatment. History of a neurological ablation procedure. Labeled contraindication for MRI. History of hemorrhagic stroke. History of HIV infection or ongoing chronic infection (such as tuberculosis). Pregnant or of childbearing potential and are not taking acceptable methods of contraception. Participation in another FDA device or medication trial that would interfere with the current study.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>